BioGaia AB: Year-end report January – December 2022
FOURTH QUARTER 2022 · Net sales amounted to SEK 274.3 million (206.2), an increase of SEK 68.1 million,...
Read moreInvitation to media and analyst briefing for BioGaia Q4 and full year 2022 report
BioGaia's (NASDAQ: BIOG) financial report for the fourth quarter and full year of 2022 will be published at approximately...
Read moreBioGaia AB: Interim report third quarter January – September 2022
THIRD QUARTER 2022 · Net sales amounted to SEK 257.7 million (173.8), an increase of SEK 83.9 million,...
Read moreInvitation to media and analyst briefing for BioGaia Q3 report 2022
BioGaia's (NASDAQ: BIOG) financial report for the third quarter 2022 will be published at approximately 8:00 AM CEST...
Read moreSkinome launches pioneering skincare probiotic following collaboration with BioGaia
BioGaia and Skinome have collaborated on the research and development of a product with live bacteria that can improve skin...
Read moreMetaboGen and BioGaia open pilot plant for new bacterial strains
BioGaia is developing probiotic products and expanding its product portfolio with new bacterial strains, developed together with the wholly-owned...
Read moreBioGaia AB Interim Management Statement – January – June 2022
SECOND QUARTER 2022 · Net sales amounted to SEK 288.1 million (203.1), an increase of SEK 85.0 million,...
Read more